Fort Lee, New Jersey, USA, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Herborium® Group, Inc. (OTC Pink: HBRM), www.Herborium.com, a Botanical Therapeutics® Company's (a provider of unique, all botanical medicines) CEO and Chairwomen Dr. Agnes P. Olszewski issued the following Letter to Shareholders today to respond to rumors of a pending reverse stock split of Herborium's stock.
We have been receiving numerous inquiries from our shareholders and others, about whether Herborium Group, Inc. is planning to undertake a reverse stock split of our outstanding securities. To dispel such rumors and clarify our position to all interested parties, we wish to inform you that we have no current plans, arrangements, contracts or understandings to undertake a reverse stock split. When and if our board of directors determines to take any material corporate actions we would undertake any such programs in full compliance with all applicable disclosure rules and in accordance with good corporate governance standards, with a focus on the best interests of the Company and its shareholders.
During the past several months, the Company has undertook a number of important initiatives and experienced a number of successful events and developments. We have systematically reported these milestones to our shareholders and the public, sharing our excitement about Herborium's growth and forthcoming opportunities. We will continue doing so as well as reconfirming our commitment to innovative work in a high demand, high growth sector of Botanical Therapeutics®.
Dr. Agnes P. Olszewski Ph.D. MBA
Chairwomen & CEO
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, and www.acnease.com.
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.
CONTACT: Contact Information: Herborium Group, Inc. Email: InvestorsRelations@Herborium.com
Source:Herborium Group, Inc.